Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: ballydog1 who wrote (13740)	6/1/2000 12:22:00 PM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

Bally you stated>>>>>>>Conflict is only in getting a drug approved with lousy data for financial gain.<<<<<<<< Where is the financial gain in getting a drug approved IF lousy data and everybody knows doesn't work by looking at the lousy data???? Who would buy stock in a company in that situation??? Btw, saying that respectful journal won't take on publishing if data pre-released doesn't hold water with me. If data is that compelling shouldn't a respectful journal take it on???? If not, how pathetic is that???? That is why once again, shine the light on the data NOW!!!!!!